首页> 美国卫生研究院文献>other >Inhalable Large Porous Microspheres of Low Molecular Weight Heparin: In Vitro and In Vivo Evaluation
【2h】

Inhalable Large Porous Microspheres of Low Molecular Weight Heparin: In Vitro and In Vivo Evaluation

机译:低分子量肝素可吸入大孔微球体的体外和体内评价

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。
获取外文期刊封面目录资料

摘要

This study tests the feasibility of large porous particles as long-acting carriers for pulmonary delivery of low molecular weight heparin (LMWH). Microspheres were prepared with a biodegradable polymer, poly(lactic-co-glycolic acid) (PLGA), by a double-emulsion–solvent-evaporation technique. The drug entrapment efficiencies of the microspheres were increased by modifying them with three different additives—polyethyleneimine (PEI), Span 60 and stearylamine. The resulting microspheres were evaluated for morphology, size, zeta potential, density, in vitro drug-release properties, cytotoxicity, and for pulmonary absorption in vivo. Scanning electron microscopic examination suggests that the porosity of the particles increased with the increase in aqueous volume fraction. The amount of aqueous volume fraction and the type of core-modifying agent added to the aqueous interior had varying degrees of effect on the size, density and aerodynamic diameter of the particles. When PEI was incorporated in the internal aqueous phase, the entrapment efficiency was increased from 16.22±1.32% to 54.82±2.79%. The amount of drug released in the initial burst phase and the release-rate constant for the core-modified microspheres were greater than those for the plain microspheres. After pulmonary administration, the half-life of the drug from the PEI- and stearylamine-modified microspheres was increased by 5- to 6-fold compared to the drug entrapped in plain microspheres. The viability of Calu-3 cells was not adversely affected when incubated with the microspheres. Overall, the data presented here suggest that the newly developed porous microspheres of LMWH have the potential to be used in a form deliverable by dry-powder inhaler as an alternative to multiple parenteral administrations of LMWH.
机译:这项研究测试了大型多孔颗粒作为长效载体用于肺部低分子量肝素(LMWH)递送的可行性。微球是用可生物降解的聚合物,聚乳酸-乙醇酸共聚物(PLGA),通过双乳液-溶剂蒸发技术制备的。通过使用三种不同的添加剂(聚乙烯亚胺(PEI),Span 60和硬脂胺)对其进行修饰,可以提高微球的药物截留效率。评价所得微球的形态,大小,ζ电势,密度,体外药物释放特性,细胞毒性和体内肺吸收。扫描电子显微镜检查表明,颗粒的孔隙率随水体积分数的增加而增加。添加到含水内部的含水体积分数的量和核心改性剂的类型对颗粒的尺寸,密度和空气动力学直径具有不同程度的影响。当将PEI掺入内部水相中时,包封率从16.22±1.32%增加至54.82±2.79%。核心修饰微球在初始爆发阶段释放的药物量和释放速率常数大于普通微球。肺部给药后,与包埋在普通微球中的药物相比,PEI和硬脂胺修饰的微球中药物的半衰期增加了5至6倍。与微球孵育时,Calu-3细胞的生存能力没有受到不利影响。总体而言,此处提供的数据表明,新开发的LMWH多孔微球有潜力以干粉吸入器可传递的形式使用,以替代LMWH的多次肠胃外给药。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号